Brieffda Approves Sglt2 Inhibitor Steglatro And Fixeddose Combination Steglujan For Adults With Type 2 Diabetes | Latest News RSS feed

Brieffda Approves Sglt2 Inhibitor Steglatro And Fixeddose Combination Steglujan For Adults With Type 2 Diabetes - Latest News


BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

Dec 22 (Reuters) - Merck & Co Inc: * FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES * MER... read more

Merck/Pfizer undercut rivals with newly approved diabetes drug

Merck and Pfizer are to take on the crowded SGLT2 inhibitor market with a keenly-priced new contender. The FDA approved Steglatro ... control in adults with type 2 diabetes. Meanwhile Steglujan (ertug... read more

FDA’s year-end approvals take annual tally to 46

Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use ... read more

Looking for another news?


Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results

Merck and Pfizer announced that the FDA approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, the fixed-dose combination STEGLUJAN ... glycemic control ... read more


Merck posts mixed fourth-quarter results

Merck and Pfizer announced that the FDA approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, the fixed-dose combination STEGLUJAN ... glycemic control ... read more

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS

The 2018 financial guidance for the effective tax rate on Adjusted income (2) reflects the enactment of the TCJA. Financial guidance for Adjusted diluted EPS (2) anticipates share repurchases totaling ... read more

PFIZER REPORTS FIRST-QUARTER 2018 RESULTS

Pfizer’s effective tax rate on Adjusted income (2) for first-quarter 2018 was ... which supported the approval of the indication extension for Bosulif for the treatment of adults with newly diagnosed ... read more

BRIEF-Agile Therapeutics Gets Response Letter From FDA For Pregnancy Prevention Drug Twirla

Dec 22 (Reuters) - Agile Therapeutics Inc: * AGILE THERAPEUTICS, INC. RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY * AGILE THERAPEUTICS - CRL ... read more

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS

The 2018 financial guidance for the effective tax rate on Adjusted income (2) reflects the enactment of the TCJA ... During 2017, Pfizer returned $12.7 billion directly to shareholders, through a comb... read more

BRIEF-Party City Announces Repurchase Of Common Stock

Dec 22 (Reuters) - Party City Holdco Inc: * PARTY CITY ANNOUNCES REPURCHASE OF COMMON STOCK * PARTY CITY HOLDCO INC - PURCHASE OF 19.8 MILLION SHARES OF COMMON STOCK FOR $242 MILLION FROM ADVENT-PARTY ... read more

BRIEF-Qualcomm Board Rejects Director Nominees Assembled By Broadcom, Silver Lake Partners (QCOM, AVGO)

Dec 22 (Reuters) - Qualcomm Inc: * QUALCOMM BOARD UNANIMOUSLY REJECTS DIRECTOR NOMINEES ASSEMBLED BY BROADCOM AND SILVER LAKE PARTNERS * QUALCOMM - FOLLOWING RECOMMENDATION OF BOARD'S GOVERNANCE COMMI... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us